MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data
Panelists discuss how bispecific antibodies have evolved in relapsed/refractory myeloma treatment, highlighting recent data developments, the importance of NCCN guideline updates, including prophylactic tocilizumab recommendations, and strategies for improving toxicity management and community practice implementation.
MonumenTAL-1 Extended Median Follow-Up Data
This Cancer Network program focuses on bispecific antibodies for relapsed/refractory myeloma, featuring an expert panel discussion on transferring clinical evidence into practice. The session brings together specialists to discuss the latest updates and developments in bispecific therapy applications for patients with multiple myeloma who have experienced disease relapse or become refractory to previous treatments.
The discussion centers on recent evolutionary changes in bispecific antibody use, particularly regarding patient population strategies and management approaches. Key developments include improved spacing strategies for patient treatment to better manage toxicity profiles, enhanced safety and effectiveness data for combination protocols, and the emergence of bispecific antibodies as viable treatment options for challenging patient cases. The experts emphasize how these advancements are reshaping treatment paradigms in the myeloma therapeutic landscape.
A significant development highlighted is the inclusion of prophylactic tocilizumab in NCCN guidelines for all bispecific antibodies as a preventive measure. This change, based on data from registration trials, is expected to facilitate broader adoption of bispecific antibodies in community practice settings. The panel notes that many treatment sites have not fully incorporated these therapies, and the prophylactic tocilizumab recommendation may help overcome implementation barriers. Additionally, new provisions for patients with extramedullary lesions under special circumstances represent another important guideline update that could expand treatment accessibility.
